Reading MGX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MGX free→Reading MGX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MGX free→QuarterlyIQ Insights · MGX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 9, 2026, Brian C. Thomas, Ph.D. informed the board of directors (the “Board”) of Metagenomi Therapeutics, Inc. (the “Company”) of his resignation from his position as a member of the Board, effective as of June 9, 2026. Dr. Thomas’ resignation from the Board was not the result of any disagreement with the Company on any matter relating to t…
Results of Operations and Financial Condition. On May 11, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and sha…
Results of Operations and Financial Condition. On March 5, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and sh…
Results of Operations and Financial Condition. On November 11, 2025, Metagenomi, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and shall n…
Entry into a Material Definitive Agreement. On September 29, 2025 (the “Effective Date”), Metagenomi, Inc. (the “Company”) entered into a Non-Exclusive License Agreement (the “Acuitas License Agreement”) with Acuitas Therapeutics, Inc. (“Acuitas”) pursuant to which Acuitas granted the Company a non-exclusive license to certain Acuitas lipid nanoparticle (“LNP”) technology, including LNP patents, formulation processes, and analytical characterization methods for manufacturing products that inc…
Termination of a Material Definitive Agreement. On September 30, 2025 (the “Termination Date”), the Company delivered to Affini-T Therapeutics, Inc. (“Affini-T”) a notice to terminate the Development, Option and License Agreement dated June 14, 2022 (the “Affini-T License Agreement”) by and between the Company and Affini-T (the “Termination”), effective immediately, due to Affini-T’s making of an assignment for the benefit of creditors, as permitted pursuant to Section 12.2.3 of the Affini-T…
Results of Operations and Financial Condition. On August 12, 2025, Metagenomi, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18…
Results of Operations and Financial Condition. On May 13, 2025, Metagenomi, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2025 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purpose…
or 7.01 of Form 8-K or to provide disclosure pursuant to
Results of Operations and Financial Condition. On March 17, 2025, Metagenomi, Inc. (the “Company”) announced its financial results for the year ended December 31, 2024 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purpo…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 13, 2025, the board of directors (the “Board”) of Metagenomi, Inc. (the “Company”) approved an increase in the size of the Board from five directors to six directors and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Eric Bjerkholt to serve as a director of the Board, each effective as of January 27,…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.